Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Key Takeaways From Stauffer and Dan
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(571)
•••
Comment by IrishCanuckon Aug 12, 2021 1:18pm
131 Views
Post# 33694713

RE:RE:RE:RE:RE:RE:RE:RE:RE:Key Takeaways From Stauffer and Dan

RE:RE:RE:RE:RE:RE:RE:RE:RE:Key Takeaways From Stauffer and Dan

No problem man. I don't have any answers to those questions, I have to take a wait and see approach to this. I'm bullish on the platform but mostly 352 so this stings but we are where we are :(


PlaySafe wrote: Thanks @IrishCanuck.  Antibe does need to plan carefully for the new Phase 2 to make sure that they statistically beat placebo otherwise game over.  Furthermore, I assume that they are not doing a Phase 2 GI study again, correct?  And since the last Phase 2 trial took over a year to complete, I'm hoping that the new one can be done in a much more timely fashion.  And after the new Phase 2 they need to re-do the AME before they can meet with FDA to discuss Phase 3.  So in your estimation how long of a delay does this put on the entire process before Phase 3 can start assuming a successful new Phase 2 at the lower dose?

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities